Monday , November 29 2021

Continuous glucose measurement provides good long-term effects


There are currently new and significantly more long-term and significantly more long-term data to measure glucose for people with type 1 diabetes. Technology that continuously monitors blood sugar levels has beneficial effects for many years. The so-called CGM (continuous monitoring of glucose), replaces the classic portable blood glucose meters, which require a stick with your finger several times a day. More and more people with type 1 diabetes have access to treatment.

With CGM, a continuous measurement of glucose is performed using a thin fiber thread under the skin, which informs the blood sugar level by phone or by extra dose. An alarm that warns of too low or high values ​​can be set.

Previous clinical trials of continuous glucose control have examined use for about six months. In the current trial, patients were evaluated for a much longer period of time, two and a half years.

Several positive effects were demonstrated

The study included 108 adult patients from 13 different hospitals in Sweden. All patients injected insulin.

Diabetes means high blood sugar

Diabetes is not just a variety of diseases with different causes. The common denominator is that blood sugar is too high.
More than 500,000 people have diabetes in Sweden today. Of these, 85-90 percent have type 2 diabetes. There are about 150,000 people in Sweden who are unaware of the disease.

In type 1 diabetes, the body stops producing insulin. Insulin can only be given as an injection, so a person with type 1 diabetes should inject insulin from the first day of illness.
In type 2 diabetes, the body still produces insulin, but there may be insulin resistance, which means that the amount of insulin is not enough.
Both types of diabetes – if left untreated – cause high blood glucose (hyperglycemia) levels.

Source: Diabetes Association

The results are published in the scientific journal Diabetes care and shows that ongoing glucose monitoring, CGM, has several long-term positive effects for people with type 1 diabetes.

The average blood sugar level dropped to a value called HbA1c of 4 mmol / mol during the trial period, which is a significant improvement in patients with less supportive care with CGM than in capillary tests, the oldest technique.

The time with a very low blood sugar level, below 3.0 mmol / l, which has a cognitive effect and is unpleasant for the patient, has been reduced by about 70 percent. Blood sugar fluctuations were reduced and patients were more comfortable with the treatment, and less afraid of too low blood sugar levels.

The technology therefore provided effects that were medically protective for patients, but also increased mental well-being and thus the chances of treatment to function well in the long run.

Treatment is not obvious everywhere

The head of the research is Marcus Lind, a professor of diabetes at the Sahlgrenska Academy at the University of Gothenburg and chief physician at Uddevalla. The same research was conducted in the NU health research unit.

– Today, most people with type 1 diabetes in Sweden receive treatment. However, it is important that decision-makers have more long-term data as a basis for funding and protecting treatments, says Marcus Lind.

– We have had periods where treatment has been questioned in some parts of the country, although it has become more and more established over time. Strong data are also important at a time when funding for various grants is increasingly being discussed, he continues.

– Research is also important from an international perspective, as treatment is not available in the world for most people with type 1 diabetes – and it also works in western countries. Long-term data are needed to allow more patients to receive treatment. Current research shows that when patients receive treatment, along with the recommended level for longer-term clinical practice, many important variables improve for people with type 1 diabetes and are therefore important worldwide with type 1 diabetes, says Marcus Lind.

Scientific article:

Sustainable Intensive Care and Long-Term Effects on A1c Reduction (SILVER Examination) in People with MDM-treated T1D by CGM, Diabetes care


Marcus Lind, Professor of Diabetology at the Sahlgrenska Academy at the University of Gothenburg and Chief Physician of Uddevalla, [email protected]

Source link